Revisiting the classic 60/40 portfolio as challenges loomTraditionally reliable, the 60/40 portfolio may no longer guarantee solid returns amid concerns about rising interest rates and rising bond yields.
Novartis Shares Leap On Positive Clinical Trial DataSwiss pharmaceutical giant Novartis leaped 5.11% in the past week following news that its Kisqali breast-cancer treatment cut the probability of relapse.
